Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review

ConclusionThis is the first study to demonstrate that HTX-019 can be safely administered via IV push in patients with cancer receiving emetogenic chemotherapy while negating the need for fluid bags, which are scarce.FundingHeron Therapeutics, Inc., San Diego, CA, USA.Plain Language SummaryPlain language summary available for this article.

http://link.springer.com/10.1007/s12325-019-0877-3

Source: Advances in Therapy - January 31, 2019 Category: Drugs & Pharmacology Source Type: research